Vivaglobin Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to improved diagnosis rates of primary immunodeficiency disorders, increased clinical acceptance of SCIg therapies, expansion of specialty pharmacy networks, availability of plasma-derived therapeutics, growing physician awareness of immune disorders.

The growth in the forecast period can be attributed to rising demand for self-administered immunoglobulin treatments, expansion of personalized immunotherapy approaches, increasing investment in rare disease treatment pipelines, growing geriatric population with immune disorders, advancements in plasma fractionation technologies. Major trends in the forecast period include increasing adoption of subcutaneous immunoglobulin therapies, rising preference for home-based treatment administration, growing focus on long-term immune replacement therapies, expansion of patient-centric dosing solutions, enhanced emphasis on treatment safety and tolerability.

The rising prevalence of primary immunodeficiency diseases (PI) is expected to significantly drive the growth of the Vivaglobin market. Primary immunodeficiency diseases are a group of disorders in which the immune system is deficient or absent, leaving the body more vulnerable to infections and illnesses. The growing prevalence of PI is attributed to improved diagnostic techniques, greater awareness and recognition of these conditions, advances in genetic testing, and better identification of previously undiagnosed cases. Vivaglobin supports patients with primary immunodeficiency diseases by providing a steady supply of antibodies through subcutaneous administration, enhancing the immune system’s ability to fight infections and reducing the frequency and severity of recurrent illnesses. For instance, in August 2023, Thermo Fisher, a US-based life sciences and clinical research company, reported that around 6 million people worldwide are estimated to have a PID, with approximately 5,000 individuals affected in the UK. Therefore, the rising prevalence of primary immunodeficiency diseases is driving the growth of the Vivaglobin market.

The increasing geriatric population is also expected to propel the growth of the Vivaglobin market. The geriatric population refers to older adults, typically aged 65 and above, who face unique health, social, and economic challenges. This population is expanding due to healthcare advancements, longer life expectancy, and declining birth rates. Vivaglobin benefits the geriatric population by offering a convenient and effective subcutaneous immunoglobulin therapy that strengthens the immune system, lowers the risk of infections, and improves overall quality of life for older adults with weakened immunity or primary immunodeficiency diseases. For instance, in May 2024, according to the Administration for Community Living, a US-based government agency, 17.3% of the US population was aged 65 or older in 2022, with projections rising to 22% by 2040. Therefore, the growing geriatric population is driving the Vivaglobin market.

Increasing investment in research and development is expected to further fuel the growth of the Vivaglobin market. Medical research and development involves investigating new drugs, treatments, or technologies to advance healthcare, including clinical trials, laboratory studies, and regulatory processes to ensure safety and efficacy. Rising R&D investment promotes innovations in immunoglobulin formulations, enhances administration methods, and improves treatment accessibility and efficacy for patients with primary immunodeficiency diseases. For instance, in April 2025, the UK Office for National Statistics reported that the government’s net R&D expenditure increased by 8.2% year-on-year, rising from £16.1 billion in 2022 to £17.4 billion in 2023. Therefore, increasing investment in research and development is driving the growth of the Vivaglobin market.

Major companies operating in the vivaglobin market are CSL Behring GmbH.

North America was the largest region in the vivaglobin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vivaglobin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vivaglobin market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the vivaglobin market by increasing costs associated with imported plasma-derived raw materials, sterile filling equipment, cold-chain logistics systems, and specialized manufacturing inputs required for immunoglobulin production. North America and Europe are particularly affected due to reliance on international plasma supply chains and cross-border biologics manufacturing. These tariffs are contributing to higher production costs and pricing pressures across hospital and specialty pharmacy channels. However, they are also encouraging domestic plasma collection, regional manufacturing expansion, and investments in localized biologics production infrastructure, supporting long-term supply stability.

The vivaglobin market research report is one of a series of new reports that provides vivaglobin market statistics, including vivaglobin industry global market size, regional shares, competitors with a vivaglobin market share, detailed vivaglobin market segments, market trends and opportunities, and any further data you may need to thrive in the vivaglobin industry. This vivaglobin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Vivaglobin is a subcutaneous immunoglobulin (SCIg) therapy used to treat patients with primary immunodeficiency (PI), a group of disorders that weaken the immune system’s ability to fight infections. It provides a continuous supply of antibodies, helping to strengthen immunity and protect against recurrent infections.

The primary indications for Vivaglobin include primary immune deficiency (PID), secondary immune deficiency (SID), chronic inflammatory demyelinating polyneuropathy (CIDP), and other conditions. Primary immune deficiency comprises genetic disorders that compromise the immune system, reducing the body’s ability to combat infections. Vivaglobin is distributed through hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies, and is used by adult, geriatric, and pediatric patients.

The vivaglobin market consists of sales of intravenous immunoglobulin (IVIG) products, subcutaneous immunoglobulin (SCIG) formulations, and hyperimmune globulin therapies. This market also encompasses associated costs for distribution, healthcare professional services, and patient support programs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.